Phase 3 readouts expected in 2027
Every Phase 3 and Phase 2/3 study on a drug AssetMemo covers whose estimated primary completion date falls in 2027, by month. The primary completion date is the sponsor's estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout, not a confirmed date. Dates move: recent moves are on the delayed readouts page, and every phase is on the readout calendar.
Summary
839 studies (738 Phase 3, 101 Phase 2/3) across 503 drugs.
| Indication | Studies |
|---|---|
| Obesity | 46 |
| Non-Small Cell Lung Cancer | 44 |
| Breast Cancer | 32 |
| Type 2 Diabetes | 26 |
| Multiple Myeloma | 22 |
| HR+/HER2- Metastatic Breast Cancer | 21 |
| Atherosclerotic Cardiovascular Disease | 17 |
| Acute Myeloid Leukemia | 16 |
| Atopic Dermatitis | 15 |
| Chronic Kidney Disease | 14 |
| Major Depressive Disorder | 12 |
| Colorectal Cancer | 11 |
January 2027
February 2027
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2027-02 (month only) | Bosentan | Johnson & Johnson | Ischemic Optic Neuropathy | Phase 3 | NCT02377271 |
| 2027-02 (month only) | metformin | Obesity, Childhood, Insulin Resistance | Phase 3 | NCT04578652 | |
| 2027-02 (month only) | Venetoclax, Azacitidine, Gemtuzumab Ozogamicin | AbbVie, Roche, Bristol-Myers Squibb | Acute Myeloid Leukemia | Phase 3 | NCT05183035 |
| 2027-02 (month only) | Carisbamate | SK Biopharmaceuticals Co., Ltd. | Epilepsy | Phase 3 | NCT05219617 |
| 2027-02 (month only) | Pembrolizumab, Sacituzumab Govitecan | Merck & Co., Gilead Sciences | Breast Cancer | Phase 3 | NCT05382286 |
| 2027-02 (month only) | CT-P53 | Celltrion | Multiple Sclerosis | Phase 3 | NCT05906992 |
| 2027-02 (month only) | orforglipron | Chugai Pharma, Eli Lilly | Obesity | Phase 3 | NCT06672549 |
| 2027-02 (month only) | CT-P51 | Celltrion | Non-Small Cell Lung Cancer | Phase 3 | NCT06939595 |
| 2027-02 (month only) | Tabirafusp alfa | Kodiak Sciences Inc. | Macular Edema Secondary to Inflammation | Phase 3 | NCT06996080 |
| 2027-02 (month only) | ribupatide | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | Type 2 Diabetes | Phase 3 | NCT07060456 |
| 2027-02 (month only) | stapokibart | Aeira Pte. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Keymed Biosciences | Atopic Dermatitis | Phase 3 | NCT07106372 |
| 2027-02 (month only) | difamilast | Acrotech Biopharma, Otsuka Holdings | Atopic Dermatitis | Phase 3 | NCT07184645 |
| 2027-02 (month only) | TQC3721 | AstraZeneca, Sino Biopharmaceutical | Chronic Obstructive Pulmonary Disease | Phase 3 | NCT07464587 |
| 2027-02 (month only) | Elismetrep | TriGemX Bio | Migraine | Phase 3 | NCT07645924 |
| 2027-02-01 | Letrozole | Novartis | Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8 | Phase 3 | NCT04095364 |
| 2027-02-01 | Apatinib, Fulvestrant | Advenchen Laboratories, Elevar Therapeutics, Inc., HLB Life Science | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06447623 |
| 2027-02-01 | Montelukast (Singulair) | Organon | Myocardial Infarction (MI) | Phase 3 | NCT07320625 |
| 2027-02-01 | Modafinil | Apotex Inc. | Inflammatory Bowel Disease (Crohn' | Phase 2/3 | NCT07582458 |
| 2027-02-02 | valproate, Haloperidol | AbbVie, Sanofi, Johnson & Johnson | Delirium, Epileptics, Neuroleptics | Phase 2/3 | NCT05431595 |
| 2027-02-03 | Levosimendan | Orion Corporation, Tenax Therapeutics | Cardiogenic Shock | Phase 3 | NCT04020263 |
| 2027-02-10 | guselkumab | Johnson & Johnson | Ulcerative Colitis | Phase 3 | NCT06260163 |
| 2027-02-10 | icotrokinra | Johnson & Johnson, Protagonist Therapeutics | Psoriatic Arthritis | Phase 3 | NCT06807424 |
| 2027-02-10 | teduglutide (Gattex) | Takeda Pharmaceutical Company | Short Bowel Syndrome | Phase 3 | NCT06973304 |
| 2027-02-14 | Tirzepatide (Zepbound) | Eli Lilly | Obesity | Phase 3 | NCT07481747 |
| 2027-02-15 | Acalabrutinib | AstraZeneca | Lymphoma, Mantle Cell | Phase 3 | NCT02972840 |
| 2027-02-16 | Repotrectinib | Bristol-Myers Squibb, Zai Lab | Non-Small Cell Lung Cancer, ROS1-Positive Non-Small Cell Lung Cancer | Phase 3 | NCT06140836 |
| 2027-02-16 | HDM1002 | Hangzhou Zhongmei Huadong Pharmaceutical | Type 2 Diabetes | Phase 3 | NCT07082114 |
| 2027-02-18 | Zibotentan + Dapagliflozin | AstraZeneca | Chronic Kidney Disease | Phase 3 | NCT06087835 |
| 2027-02-20 | Capecitabine | Cheplapharm Arzneimittel GmbH | Nasopharyngeal Carcinoma | Phase 3 | NCT06239727 |
| 2027-02-20 | Cenvacibart | Regeneron Pharmaceuticals | Venous Thromboembolism | Phase 3 | NCT07015905 |
| 2027-02-20 | AND017 | Kind Pharmaceuticals | Chronic Kidney Disease | Phase 3 | NCT07494409 |
| 2027-02-22 | Acalabrutinib | AstraZeneca | Diffuse Large B-Cell Lymphoma | Phase 3 | NCT04529772 |
| 2027-02-22 | Osimertinib | AstraZeneca | Cancer | Phase 3 | NCT05629234 |
| 2027-02-22 | Laroprovstat | AstraZeneca | Atherosclerotic Cardiovascular Disease | Phase 2/3 | NCT06834932 |
| 2027-02-22 | remibrutinib | Novartis | Chronic Spontaneous Urticaria | Phase 3 | NCT06868212 |
| 2027-02-23 | Anifrolumab | AstraZeneca, MedImmune LLC | Systemic Lupus Erythematosus | Phase 3 | NCT05138133 |
| 2027-02-23 | Suzetrigine | Vertex Pharmaceuticals | Total Knee Replacement Surgery, Post-operative Pain | Phase 3 | NCT07548385 |
| 2027-02-24 | IncobotulinumtoxinA (Xeomin) | Merz Pharmaceuticals | Migraine | Phase 3 | NCT05598723 |
| 2027-02-25 | Abemaciclib | Eli Lilly | Breast Cancer | Phase 3 | NCT06341621 |
| 2027-02-26 | Everolimus | Novartis | Epilepsy | Phase 3 | NCT02962414 |
| 2027-02-26 | Alpelisib (BYL719) | Novartis | Breast Cancer | Phase 3 | NCT04208178 |
| 2027-02-26 | Tenapanor (Ibsrela) | Ardelyx, Knight Therapeutics | Chronic Idiopathic Constipation (CIC) | Phase 3 | NCT07382167 |
| 2027-02-28 | metformin | Intermittent Claudication | Phase 3 | NCT05132439 | |
| 2027-02-28 | Mevrometostat | Pfizer | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 3 | NCT06551324 |
March 2027
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2027-03 (month only) | Epirubicin | Pfizer | Breast Cancer | Phase 3 | NCT02455141 |
| 2027-03 (month only) | Rituximab | Biogen, Chugai Pharma, Roche | Severe Forms of Mucous Membrane Pemphigoid | Phase 3 | NCT03295383 |
| 2027-03 (month only) | Anakinra | Swedish Orphan Biovitrum AB (publ) | Kawasaki Disease | Phase 3 | NCT04656184 |
| 2027-03 (month only) | Cariprazine (Vraylar) | AbbVie, Gedeon Richter, Tanabe Pharma Corporation | Bipolar Disorder | Phase 3 | NCT04777357 |
| 2027-03 (month only) | baricitinib | Eli Lilly, Incyte | Rheumatoid Arthritis | Phase 3 | NCT04870203 |
| 2027-03 (month only) | Resmetirom | Madrigal Pharmaceuticals | MASH / NASH | Phase 3 | NCT04951219 |
| 2027-03 (month only) | Atezolizumab, Bevacizumab, Ipilimumab | Chugai Pharma, Roche, Bristol-Myers Squibb | Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer | Phase 2/3 | NCT05141721 |
| 2027-03 (month only) | Olezarsen | Ionis Pharmaceuticals, Swedish Orphan Biovitrum AB (publ), Theratechnologies | Severe Hypertriglyceridemia, Hypertriglyceridemia | Phase 3 | NCT05681351 |
| 2027-03 (month only) | upadacitinib | AbbVie | Systemic Lupus Erythematosus | Phase 3 | NCT05843643 |
| 2027-03 (month only) | risankizumab | AbbVie, Boehringer Ingelheim | Crohn's Disease | Phase 3 | NCT06063967 |
| 2027-03 (month only) | Telitacicept | RemeGen Co., Ltd., Vor Bio | Generalized Myasthenia Gravis | Phase 3 | NCT06456580 |
| 2027-03 (month only) | Zorevunersen | Biogen, Stoke Therapeutics, Inc. | Dravet Syndrome | Phase 3 | NCT06872125 |
| 2027-03 (month only) | QLM3003 | Qilu Pharmaceutical | Atopic Dermatitis | Phase 3 | NCT06880276 |
| 2027-03 (month only) | Rituximab, SHR-A1912 | Biogen, Chugai Pharma, Roche | Diffuse Large B-Cell Lymphoma | Phase 3 | NCT06929624 |
| 2027-03 (month only) | IncobotulinumtoxinA (Xeomin) | Merz Pharmaceuticals | Migraine | Phase 3 | NCT07018700 |
| 2027-03 (month only) | IncobotulinumtoxinA (Xeomin) | Merz Pharmaceuticals | Migraine | Phase 3 | NCT07018713 |
| 2027-03 (month only) | TQC3721 | AstraZeneca, Sino Biopharmaceutical | Chronic Obstructive Pulmonary Disease | Phase 3 | NCT07147946 |
| 2027-03 (month only) | Axitinib intravitreal implant (OTX-TKI) | OCULAR THERAPEUTIX, INC | Non-Proliferative Diabetic Retinopathy | Phase 3 | NCT07235085 |
| 2027-03 (month only) | Rezvilutamide | Jiangsu Hengrui Pharmaceuticals | Prostate Cancer | Phase 3 | NCT07241416 |
| 2027-03 (month only) | ribupatide | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | Obesity | Phase 3 | NCT07285902 |
| 2027-03 (month only) | SHR-1918 | Jiangsu Hengrui Pharmaceuticals | Hypertriglyceridemia | Phase 3 | NCT07349615 |
| 2027-03 (month only) | Arsenic trioxide (QTX-2101) | Quetzal Therapeutics | Acute Myeloid Leukemia | Phase 3 | NCT07504458 |
| 2027-03-01 | Rituximab, Azacitidine (Onureg) | Biogen, Chugai Pharma, Roche | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2/3 | NCT04799275 |
| 2027-03-01 | Utidelone, Capecitabine | Beijing Biostar Pharmaceuticals, Cheplapharm Arzneimittel GmbH | HR+/HER2- Metastatic Breast Cancer | Phase 3 | NCT05172518 |
| 2027-03-01 | Recaticimab | Jiangsu Hengrui Pharmaceuticals | Stroke | Phase 3 | NCT07002476 |
| 2027-03-01 | cagrilintide/semaglutide | Novo Nordisk | Obesity | Phase 3 | NCT07011667 |
| 2027-03-01 | AND017 | Kind Pharmaceuticals | Chronic Kidney Disease | Phase 3 | NCT07487727 |
| 2027-03-01 | Depemokimab | GlaxoSmithKline | Asthma | Phase 3 | NCT07671001 |
| 2027-03-01 | Gabapentin | Pfizer, Viatris | Postdural Puncture Headache (PDPH) | Phase 2/3 | NCT07916116 |
| 2027-03-08 | Daratumumab, CT-P44 | Johnson & Johnson, Celltrion | Multiple Myeloma | Phase 3 | NCT06952478 |
| 2027-03-09 | bimekizumab | UCB | Psoriatic Arthritis, Psoriasis | Phase 3 | NCT06506916 |
| 2027-03-11 | Nivolumab, Ipilimumab | Bristol-Myers Squibb, Ono Pharmaceutical | Renal Cell Carcinoma | Phase 3 | NCT03873402 |
| 2027-03-13 | setmelanotide | Rhythm Pharmaceuticals | Obesity, Hypothalamic Obesity | Phase 3 | NCT06760546 |
| 2027-03-15 | Rucaparib | pharmaand | Prostate Cancer | Phase 3 | NCT04455750 |
| 2027-03-16 | Apadamtase alfa | Takeda Pharmaceutical Company | Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | NCT04683003 |
| 2027-03-16 | Empagliflozin | Boehringer Ingelheim, Eli Lilly | Cardiogenic Shock | Phase 3 | NCT05879276 |
| 2027-03-17 | tofacitinib | Pfizer | Ulcerative Colitis | Phase 3 | NCT04624230 |
| 2027-03-18 | Rituximab | Biogen, Chugai Pharma, Roche | Marginal Zone Lymphoma | Phase 3 | NCT04212013 |
| 2027-03-20 | Olanzapine (Zyprexa) | Cheplapharm Arzneimittel GmbH, Eli Lilly | Advanced Cancer, Olanzapine, Progression Free Survival | Phase 3 | NCT06338683 |
| 2027-03-20 | Roflumilast (Daliresp) | AstraZeneca | Depressive Disorder, Major | Phase 3 | NCT06860958 |
| 2027-03-20 | Vildagliptin | Cipla, Novartis, Sumitomo Pharma | Poly Cystic Ovary Syndrome | Phase 2/3 | NCT07811011 |
| 2027-03-22 | Cemiplimab, Fianlimab | Regeneron Pharmaceuticals | Melanoma | Phase 3 | NCT06246916 |
| 2027-03-23 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | HR+/HER2- Breast Cancer | Phase 3 | NCT06977893 |
| 2027-03-25 | guselkumab | Johnson & Johnson | Crohn's Disease | Phase 3 | NCT05347095 |
| 2027-03-25 | Fitusiran | Alnylam Pharmaceuticals, Sanofi | Hemophilia | Phase 3 | NCT05662319 |
| 2027-03-26 | Eptinezumab (Vyepti) | H. Lundbeck | Migraine | Phase 3 | NCT04965675 |
| 2027-03-26 | VAY736 | Novartis | Systemic Lupus Erythematosus | Phase 3 | NCT05639114 |
| 2027-03-26 | Osimertinib, Becotatug | AstraZeneca, Shanghai JMT-Bio | Non-Small Cell Lung Cancer | Phase 3 | NCT06380348 |
| 2027-03-28 | Pertuzumab | Roche | Solid Tumors | Phase 3 | NCT02320435 |
| 2027-03-29 | Staccato Alprazolam | Nova Pneuma Inc., UCB | Epilepsy | Phase 3 | NCT05077904 |
| 2027-03-30 | Sacituzumab Govitecan, Capecitabine | Gilead Sciences, Cheplapharm Arzneimittel GmbH | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT04595565 |
| 2027-03-30 | Ferric derisomaltose | China Medical System, Nippon Shinyaku, Pfizer | Iron Deficiency Anemia | Phase 3 | NCT05462704 |
| 2027-03-30 | olatorepatide | Hansoh Pharmaceutical Group, Regeneron Pharmaceuticals | Type 2 Diabetes | Phase 3 | NCT07156500 |
| 2027-03-30 | olatorepatide | Hansoh Pharmaceutical Group, Regeneron Pharmaceuticals | Type 2 Diabetes | Phase 3 | NCT07156539 |
| 2027-03-31 | Nivolumab, Ipilimumab | Bristol-Myers Squibb, Ono Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT03391869 |
| 2027-03-31 | Gemcitabine | Eli Lilly | Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified | Phase 3 | NCT03533582 |
| 2027-03-31 | Nivolumab | Bristol-Myers Squibb, Ono Pharmaceutical | Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma | Phase 3 | NCT04444921 |
| 2027-03-31 | Atezolizumab | Chugai Pharma, Roche | Breast Cancer | Phase 3 | NCT04873362 |
| 2027-03-31 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Gastric or Esophagogastric Junction Adenocarcinoma | Phase 3 | NCT05180734 |
| 2027-03-31 | Binimetinib, Encorafenib | Ono Pharmaceutical, Pfizer, Pierre Fabre Medicament | Melanoma | Phase 3 | NCT05270044 |
| 2027-03-31 | Regorafenib | Bayer | Colorectal Cancer | Phase 3 | NCT05794971 |
| 2027-03-31 | PF-06651600 | Pfizer | Vitiligo | Phase 3 | NCT06163326 |
| 2027-03-31 | Liraglutide (Victoza) | Novo Nordisk | Delirium, Postoperative | Phase 3 | NCT06361238 |
| 2027-03-31 | Pomalidomide, Sanritatug, Dexamethasone | Bristol-Myers Squibb, Hangzhou Sumgen Biotech Co., Ltd. | Multiple Myeloma | Phase 3 | NCT06508983 |
| 2027-03-31 | Olverembatinib | Ascentage Pharma Group Inc., Innovent Biologics | GIST | Phase 3 | NCT06640361 |
| 2027-03-31 | HS-20137 | Hansoh Pharmaceutical Group, Qyuns Therapeutics | Psoriasis | Phase 3 | NCT06844799 |
| 2027-03-31 | IFx-2.0 | TuHURA Biosciences | Merkel Cell Carcinoma | Phase 2/3 | NCT06947928 |
| 2027-03-31 | metformin | Obesity and Cardiovascular Risk, Insulin Resistance, Obesity (Body Mass Index > | Phase 3 | NCT07297290 | |
| 2027-03-31 | Neovasculgen | Artgen Biotech | Ulcer Foot, Mellitus Diabetes | Phase 3 | NCT07391319 |
| 2027-03-31 | Suzetrigine | Vertex Pharmaceuticals | Opioid Consumption, Postoperative, Multimodal Analgesia, Ureteroscopy, Ureteral Stents, Ureteral Stent-Related Symptoms | Phase 3 | NCT07654296 |
April 2027
May 2027
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2027-05 (month only) | Lovotibeglogene autotemcel (Lyfgenia) | Genetix Biotherapeutics Inc. (formerly bluebird bio, Inc.), SPIMACO | Sickle Cell Disease | Phase 3 | NCT04293185 |
| 2027-05 (month only) | Ubrogepant (Ubrelvy) | AbbVie | Migraine | Phase 3 | NCT05125302 |
| 2027-05 (month only) | mocravimod | Priothera SAS | Acute Myeloid Leukemia | Phase 3 | NCT05429632 |
| 2027-05 (month only) | Rituximab | Biogen, Chugai Pharma, Roche | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases | Phase 3 | NCT05834855 |
| 2027-05 (month only) | Fampridine | Merz Therapeutics | Multiple Sclerosis | Phase 3 | NCT06136728 |
| 2027-05 (month only) | Dexamethasone | Rheumatic Fever, Sydenham Chorea | Phase 3 | NCT06259006 | |
| 2027-05 (month only) | lebrikizumab | Almirall, Eli Lilly | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 3 | NCT06338995 |
| 2027-05 (month only) | Pumitamig | BioNTech, Bristol-Myers Squibb | Small Cell Lung Cancer | Phase 3 | NCT06616532 |
| 2027-05 (month only) | upadacitinib | AbbVie | Ulcerative Colitis | Phase 3 | NCT06660693 |
| 2027-05 (month only) | Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | Phase 3 | NCT06670196 |
| 2027-05 (month only) | Trastuzumab rezetecan | Glenmark Pharmaceuticals Ltd., Jiangsu Hengrui Pharmaceuticals | Ovarian Cancer | Phase 3 | NCT06828354 |
| 2027-05 (month only) | QL2108 | Qilu Pharmaceutical | Atopic Dermatitis | Phase 3 | NCT06884891 |
| 2027-05 (month only) | onabotulinumtoxinA | AbbVie | Base-of-thumb Osteoarthritis, Osteoarthritis | Phase 2/3 | NCT06902805 |
| 2027-05 (month only) | Ivonescimab | Akeso, Summit Therapeutics | Non-Small Cell Lung Cancer | Phase 3 | NCT06928389 |
| 2027-05 (month only) | Trastuzumab brengitecan | Sichuan Baili Pharmaceutical | HER2-low Breast Cancer | Phase 3 | NCT06957886 |
| 2027-05 (month only) | Azetukalner | Xenon Pharmaceuticals | Major Depressive Disorder | Phase 3 | NCT07076407 |
| 2027-05 (month only) | Alixorexton | Alkermes plc | Narcolepsy | Phase 3 | NCT07455383 |
| 2027-05 (month only) | Alixorexton | Alkermes plc | Narcolepsy | Phase 3 | NCT07502443 |
| 2027-05 (month only) | orforglipron | Chugai Pharma, Eli Lilly | Type 2 Diabetes | Phase 3 | NCT07613307 |
| 2027-05-01 | Empagliflozin | Boehringer Ingelheim, Eli Lilly | Chronic Kidney Disease | Phase 3 | NCT05715814 |
| 2027-05-01 | Camrelizumab | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals | Hepatocellular Carcinoma | Phase 3 | NCT05738616 |
| 2027-05-01 | Dapagliflozin, Finerenone | AstraZeneca, Ono Pharmaceutical, Bayer | Type 2 Diabetes, Chronic Kidney Disease | Phase 3 | NCT07598864 |
| 2027-05-02 | abrocitinib | Pfizer | Eczema | Phase 3 | NCT06807268 |
| 2027-05-03 | Trastuzumab Deruxtecan, Pertuzumab | AstraZeneca, Daiichi Sankyo, Roche | Breast Cancer | Phase 3 | NCT04784715 |
| 2027-05-03 | Inavolisib | Roche | Breast Cancer | Phase 3 | NCT05894239 |
| 2027-05-05 | Pembrolizumab, Olaparib, pemetrexed | Merck & Co., AstraZeneca, Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT04380636 |
| 2027-05-06 | Frexalimab | Sanofi | Multiple Sclerosis | Phase 3 | NCT06141473 |
| 2027-05-07 | mazdutide | Eli Lilly, Innovent Biologics | Obesity | Phase 3 | NCT06931028 |
| 2027-05-08 | Capsaicin (Qutenza) | Apotex Inc., BCWorld Pharm, Clinect | Coccyx Disorder, Neuropathic Pain, Coccygodynia | Phase 3 | NCT06023706 |
| 2027-05-10 | Inclisiran | Alnylam Pharmaceuticals, Novartis | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT05030428 |
| 2027-05-10 | Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | Phase 3 | NCT06074588 |
| 2027-05-11 | cagrilintide | Novo Nordisk | Obesity | Phase 3 | NCT07220642 |
| 2027-05-12 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | Phase 3 | NCT04848753 |
| 2027-05-12 | cagrilintide | Novo Nordisk | Obesity, Type 2 Diabetes | Phase 3 | NCT07220759 |
| 2027-05-12 | RC148, Capecitabine | AbbVie, RemeGen Co., Ltd., Cheplapharm Arzneimittel GmbH | Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2/3 | NCT07462143 |
| 2027-05-14 | Nab-paclitaxel, Ivonescimab, Ligufalimab | Bristol-Myers Squibb, Akeso, Summit Therapeutics | Pancreatic Cancer | Phase 3 | NCT06953999 |
| 2027-05-15 | Tislelizumab | BeOne Medicines | Nasopharyngeal Carcinoma | Phase 3 | NCT06383780 |
| 2027-05-15 | Entecavir (Baraclude) | Bristol-Myers Squibb | Chronic Hepatitis B | Phase 3 | NCT06966232 |
| 2027-05-15 | Telikibart | Genrix Bio | Allergic Rhinitis, Seasonal | Phase 3 | NCT07199257 |
| 2027-05-17 | remibrutinib | Novartis | Hidradenitis Suppurativa | Phase 3 | NCT06799000 |
| 2027-05-17 | Cenvacibart | Regeneron Pharmaceuticals | Venous Thromboembolism | Phase 3 | NCT07213778 |
| 2027-05-18 | zasocitinib | Takeda Pharmaceutical Company | Psoriatic Arthritis | Phase 3 | NCT06671483 |
| 2027-05-18 | zasocitinib | Takeda Pharmaceutical Company | Psoriatic Arthritis | Phase 3 | NCT06671496 |
| 2027-05-18 | cagrilintide | Novo Nordisk | Obesity | Phase 3 | NCT07745504 |
| 2027-05-19 | Nemtabrutinib | Merck & Co. | Chronic Lymphocytic Leukemia | Phase 3 | NCT05624554 |
| 2027-05-20 | peginterferon beta-1a | Biogen | Multiple Sclerosis | Phase 3 | NCT03958877 |
| 2027-05-21 | Fampridine | Merz Therapeutics | Spinocerebellar Ataxia 27B (SCA27B) | Phase 3 | NCT07185347 |
| 2027-05-27 | Pembrolizumab | Merck & Co. | Endometrial Neoplasms | Phase 3 | NCT05173987 |
| 2027-05-27 | Zipalertinib | Cullinan Therapeutics Inc., Taiho Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT05973773 |
| 2027-05-27 | Centanafadine | Otsuka Holdings | Attention Deficit Hyperactivity Disorder | Phase 3 | NCT07759154 |
| 2027-05-28 | Ravulizumab, Eculizumab | AstraZeneca, Alexion Pharmaceuticals, Inc. (subsidiary of AstraZeneca) | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | NCT06449001 |
| 2027-05-28 | Rosuvastatin, laroprovstat/rosuvastatin | AstraZeneca, Shionogi | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07619118 |
| 2027-05-29 | zovaglutide | Beijing QL Biopharmaceutical | Obesity | Phase 3 | NCT07230119 |
| 2027-05-30 | zasocitinib | Takeda Pharmaceutical Company | Psoriasis | Phase 3 | NCT07752108 |
| 2027-05-31 | Nivolumab | Bristol-Myers Squibb, Ono Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT02595944 |
| 2027-05-31 | Pembrolizumab | Merck & Co. | Non-Small Cell Lung Cancer | Phase 3 | NCT05085028 |
| 2027-05-31 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Cholangiocarcinoma | Phase 3 | NCT05342194 |
| 2027-05-31 | Zoledronic acid | Novartis | Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | Phase 3 | NCT06221072 |
| 2027-05-31 | Suzetrigine | Vertex Pharmaceuticals | Diabetic Peripheral Neuropathic Pain | Phase 3 | NCT06628908 |
| 2027-05-31 | Felzartamab | Biogen | IgA Nephropathy | Phase 3 | NCT06935357 |
| 2027-05-31 | tanruprubart | Annexon, Inc. | Guillain-Barré Syndrome | Phase 3 | NCT07020819 |
| 2027-05-31 | Neovasculgen | Artgen Biotech | IC, Interstitial Cystitis and Bladder Pain Syndrome, Interstitial Cystitis, Chronic | Phase 2/3 | NCT07391306 |
| 2027-05-31 | Ivabradine | Amgen, Servier | Cardiogenic Shock Post Myocardial Infarction | Phase 3 | NCT07714746 |
June 2027
July 2027
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2027-07 (month only) | upadacitinib | AbbVie | Ulcerative Colitis | Phase 3 | NCT03006068 |
| 2027-07 (month only) | Fampridine | Merz Therapeutics | Nerve Injury, Prostate Cancer | Phase 2/3 | NCT03701581 |
| 2027-07 (month only) | Fosigotifator | AbbVie, Calico Life Sciences LLC | Amyotrophic Lateral Sclerosis | Phase 2/3 | NCT04297683 |
| 2027-07 (month only) | Venetoclax | AbbVie, Roche | Myelodysplastic Syndrome (MDS) | Phase 3 | NCT04401748 |
| 2027-07 (month only) | Denosumab (Xgeva) | Amgen, Daiichi Sankyo | HR+/HER2- Metastatic Breast Cancer | Phase 3 | NCT04711109 |
| 2027-07 (month only) | Atezolizumab, Bevacizumab | Chugai Pharma, Roche | Hepatocellular Carcinoma | Phase 3 | NCT04803994 |
| 2027-07 (month only) | Mitizodone phosphate | Sunshine Lake Pharma | Major Depressive Disorder | Phase 2/3 | NCT04984512 |
| 2027-07 (month only) | Pertuzumab | Roche | Esophageal Cancer, Esophageal Adenocarcinoma | Phase 3 | NCT05188313 |
| 2027-07 (month only) | Dapagliflozin | AstraZeneca, Ono Pharmaceutical | Heart Failure, Chronic Kidney Disease | Phase 3 | NCT05374291 |
| 2027-07 (month only) | Pegcetacoplan | Apellis Pharmaceuticals, Biogen, Swedish Orphan Biovitrum AB (publ) | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 3 | NCT05809531 |
| 2027-07 (month only) | rexlemestrocel-L | Grünenthal GmbH, Mesoblast, Tasly Pharmaceutical Group | Chronic Low Back Pain | Phase 3 | NCT06325566 |
| 2027-07 (month only) | Pumitamig | BioNTech, Bristol-Myers Squibb | Triple Negative Breast Cancer(TNBC) | Phase 3 | NCT06419621 |
| 2027-07 (month only) | Nexiguran ziclumeran | Regeneron Pharmaceuticals | Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary, Neurodegenerative Diseases, Neuromuscular Diseases, Nerve Disorders, Nervous System Disease, Nervous System Diseases, Genetic Disease, Inborn, Amyloidosis, Familial, Amyloidosis, Hereditary, Amyloidosis, Polyneuropathies, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Peripheral Nervous System Disease, Peripheral Nervous System Diseases, Metabolism, Inborn Errors, Metabolic Diseases | Phase 3 | NCT06672237 |
| 2027-07 (month only) | Osavampator | Neurocrine Biosciences, Takeda Pharmaceutical Company | Major Depressive Disorder | Phase 3 | NCT06786624 |
| 2027-07 (month only) | HLX15 | Dr. Reddy's Laboratories, Shanghai Henlius Biotech | Multiple Myeloma | Phase 3 | NCT06895512 |
| 2027-07 (month only) | Osavampator | Neurocrine Biosciences, Takeda Pharmaceutical Company | Major Depressive Disorder | Phase 3 | NCT06911112 |
| 2027-07 (month only) | Osavampator | Neurocrine Biosciences, Takeda Pharmaceutical Company | Major Depressive Disorder | Phase 3 | NCT06963021 |
| 2027-07 (month only) | Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07071337 |
| 2027-07 (month only) | Serplulimab | Abbott, Accord Healthcare, Eisai | PDAC - Pancreatic Ductal Adenocarcinoma | Phase 3 | NCT07336953 |
| 2027-07 (month only) | SCTB14 | Sinocelltech Group Ltd. | Non-Small Cell Lung Cancer | Phase 3 | NCT07362459 |
| 2027-07 (month only) | Suzetrigine | Vertex Pharmaceuticals | Analgesic Efficacy | Phase 3 | NCT07525219 |
| 2027-07 (month only) | Dapagliflozin | AstraZeneca, Ono Pharmaceutical | Ascites Hepatic | Phase 2/3 | NCT07684326 |
| 2027-07-01 | XY0206 | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Acute Myeloid Leukemia | Phase 3 | NCT05876832 |
| 2027-07-01 | VK2735 | Viking Therapeutics | Obesity, Type 2 Diabetes | Phase 3 | NCT07104383 |
| 2027-07-01 | VK2735 | Viking Therapeutics | Obesity | Phase 3 | NCT07104500 |
| 2027-07-02 | MK-1406 | Merck & Co. | Influenza | Phase 3 | NCT07159763 |
| 2027-07-06 | Eptinezumab (Vyepti) | H. Lundbeck | Migraine | Phase 3 | NCT05897320 |
| 2027-07-09 | Riliprubart | Sanofi | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | NCT06290141 |
| 2027-07-09 | Sintilimab | Innovent Biologics | Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE, Narrow Margin | Phase 3 | NCT07186621 |
| 2027-07-09 | DA-302168S | Chendu DIAO Pharmaceutical Group | Obesity | Phase 3 | NCT07629544 |
| 2027-07-10 | Venetoclax, Rituximab | AbbVie, Roche, Biogen | Mantle Cell Lymphoma (MCL) | Phase 3 | NCT06496308 |
| 2027-07-10 | Manfidokimab | Akeso | Atopic Dermatitis | Phase 3 | NCT06767540 |
| 2027-07-11 | Pembrolizumab, Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06312176 |
| 2027-07-12 | Nomelcitinib (D-2570) | InventisBio | Psoriasis | Phase 3 | NCT07326813 |
| 2027-07-14 | Bomedemstat | Merck & Co. | Essential Thrombocythemia | Phase 3 | NCT06079879 |
| 2027-07-15 | Venetoclax, Obinutuzumab, Acalabrutinib | AbbVie, Roche, AstraZeneca | Chronic Lymphocytic Leukemia | Phase 3 | NCT05057494 |
| 2027-07-15 | Frexalimab | Sanofi | Multiple Sclerosis | Phase 3 | NCT07325292 |
| 2027-07-18 | Avacopan | Amgen, Vifor Pharma | Vasculitis | Phase 3 | NCT06321601 |
| 2027-07-21 | S-1, Capecitabine | Nordic Group B.V., Taiho Pharmaceutical, Cheplapharm Arzneimittel GmbH | Gastric Cancer | Phase 3 | NCT04997837 |
| 2027-07-22 | Alimatravir | Merck & Co. | HIV, HIV Pre-Exposure Prophylaxis | Phase 3 | NCT07044297 |
| 2027-07-22 | Everolimus, Fulvestrant, Exemestane, Prifetrastat | Novartis, AstraZeneca, Pfizer | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07062965 |
| 2027-07-23 | rilzabrutinib | Sanofi | Sickle Cell Disease | Phase 3 | NCT06975865 |
| 2027-07-27 | Baxdrostat | AstraZeneca, Roche | Primary Hyperaldosteronism | Phase 3 | NCT07007793 |
| 2027-07-28 | Durvalumab, Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | Breast Cancer | Phase 3 | NCT06103864 |
| 2027-07-28 | Nomelcitinib (D-2570) | InventisBio | Psoriasis | Phase 3 | NCT07130604 |
| 2027-07-30 | Atezolizumab | Chugai Pharma, Roche | Mesotheliomas Pleural | Phase 3 | NCT04996017 |
| 2027-07-30 | Daratumumab, Pomalidomide, Talquetamab | Johnson & Johnson, Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT05455320 |
| 2027-07-30 | faricimab | Chugai Pharma, Roche | Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration | Phase 3 | NCT05904028 |
| 2027-07-30 | PF-06651600 | Pfizer | Vitiligo | Phase 3 | NCT06072183 |
| 2027-07-30 | Crisugabalin | Haisco Pharmaceutical Group | Central Neuropathic Pain | Phase 3 | NCT06422117 |
| 2027-07-30 | Sodium zirconium cyclosilicate | AstraZeneca | Chronic Kidney Disease | Phase 3 | NCT06578533 |
| 2027-07-30 | Pembrolizumab | Merck & Co. | Non-Small Cell Lung Cancer | Phase 3 | NCT06635824 |
| 2027-07-30 | Laroprovstat, Rosuvastatin, laroprovstat/rosuvastatin | AstraZeneca, Shionogi | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07619131 |
| 2027-07-31 | metreleptin | Chiesi Farmaceutici | Lipodystrophy, Diabetes, Hyperlipidemia | Phase 3 | NCT02262832 |
| 2027-07-31 | Ribociclib | Novartis | Breast Cancer | Phase 3 | NCT04055493 |
| 2027-07-31 | Sintilimab, Bevacizumab | Innovent Biologics, Roche | Hepatocellular Carcinoma | Phase 3 | NCT05985798 |
| 2027-07-31 | Toripalimab | Coherus BioSciences, Inc., Shanghai Junshi Bioscience | Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | NCT06095583 |
| 2027-07-31 | Vonaprument | Annexon, Inc. | Age-Related Macular Degeneration, Geographic Atrophy | Phase 3 | NCT06510816 |
| 2027-07-31 | Cemiplimab, Ateganosine (THIO) | Regeneron Pharmaceuticals, Maia Biotechnology | Non-Small Cell Lung Cancer | Phase 3 | NCT06908304 |
| 2027-07-31 | Serplulimab | Abbott, Accord Healthcare, Eisai | Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy, Anal Function Preservation | Phase 3 | NCT07020247 |
| 2027-07-31 | Semaglutide (Ozempic) | Novo Nordisk | Acute Ischemic Stroke | Phase 3 | NCT07030621 |
August 2027
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2027-08 (month only) | Bortezomib, Thalidomide, Dexamethasone | Janssen, Takeda Pharmaceutical Company, Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT00572169 |
| 2027-08 (month only) | Capecitabine | Cheplapharm Arzneimittel GmbH | Adenocarcinoma of the Rectum | Phase 2/3 | NCT02945566 |
| 2027-08 (month only) | Nivolumab | Bristol-Myers Squibb, Ono Pharmaceutical | Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT03576417 |
| 2027-08 (month only) | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia, Multiple Myeloma, Chronic Lymphocytic Leukemia | Phase 3 | NCT03844048 |
| 2027-08 (month only) | Bortezomib, Lenalidomide, Isatuximab, Dexamethasone | Janssen, Takeda Pharmaceutical Company, Bristol-Myers Squibb | Multiple Myeloma | Phase 2/3 | NCT05665140 |
| 2027-08 (month only) | Dalcetrapib | DalCor Pharmaceuticals, Shionogi | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT05918861 |
| 2027-08 (month only) | Lisaftoclax, Acalabrutinib | Ascentage Pharma Group Inc., AstraZeneca | CLL/SLL | Phase 3 | NCT06319456 |
| 2027-08 (month only) | Equecabtagene autoleucel | IASO Biotherapeutics | Multiple Myeloma | Phase 3 | NCT06464991 |
| 2027-08 (month only) | risankizumab, vedolizumab | AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical Company | Ulcerative Colitis | Phase 3 | NCT06880744 |
| 2027-08 (month only) | Obudanersen | Ionis Pharmaceuticals | Angelman Syndrome | Phase 3 | NCT06914609 |
| 2027-08 (month only) | orforglipron | Chugai Pharma, Eli Lilly | Obesity | Phase 3 | NCT06972459 |
| 2027-08 (month only) | orforglipron | Chugai Pharma, Eli Lilly | Obesity, Type 2 Diabetes | Phase 3 | NCT06972472 |
| 2027-08 (month only) | BHV-8000 | Biohaven, Hangzhou Highlightll Pharmaceutical | Parkinson's Disease | Phase 2/3 | NCT06976268 |
| 2027-08 (month only) | orforglipron | Chugai Pharma, Eli Lilly | Obesity, Type 2 Diabetes | Phase 3 | NCT06993792 |
| 2027-08 (month only) | HRS-8080 | Jiangsu Hengrui Pharmaceuticals | HR+/HER2- Metastatic Breast Cancer | Phase 3 | NCT07024173 |
| 2027-08 (month only) | Centanafadine | Otsuka Holdings | Attention Deficit Hyperactivity Disorder | Phase 2/3 | NCT07086313 |
| 2027-08 (month only) | Centanafadine | Otsuka Holdings | Attention Deficit Hyperactivity Disorder | Phase 3 | NCT07087327 |
| 2027-08 (month only) | Tapinarof | Organon, Shionogi, Torii Pharmaceutical | Atopic Dermatitis | Phase 3 | NCT07265479 |
| 2027-08 (month only) | Bempedoic acid | CSL Seqirus, Daiichi Sankyo, Esperion Therapeutics | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07440381 |
| 2027-08 (month only) | Regorafenib, Fruquintinib | Bayer, HUTCHMED, Takeda Pharmaceutical Company | Colorectal Cancer | Phase 3 | NCT07483684 |
| 2027-08 (month only) | palopegteriparatide | Ascendis Pharma A/S, Pendopharm, Teijin | Hypoparathyroidism | Phase 3 | NCT07706764 |
| 2027-08 (month only) | Cariprazine (Vraylar) | AbbVie, Gedeon Richter, Tanabe Pharma Corporation | Schizophrenia | Phase 2/3 | NCT07722728 |
| 2027-08 (month only) | Brexpiprazole (Rexulti) | H. Lundbeck, Otsuka Holdings | Schizophrenia | Phase 2/3 | NCT07742280 |
| 2027-08 (month only) | Suzetrigine | Vertex Pharmaceuticals | Post-operative Pain, DIEP Flap Breast Reconstruction, DIEP Flap, Opioid, Suzetrigine, ERAS | Phase 3 | NCT07839715 |
| 2027-08 (month only) | Denifanstat | Ascletis Pharma, Sagimet Biosciences Inc. | Acne Vulgaris | Phase 3 | NCT07863193 |
| 2027-08 (month only) | Nalbuphine ER | Trevi Therapeutics, Inc. | Chronic Cough in Idiopathic Pulmonary Fibrosis | Phase 3 | NCT07868419 |
| 2027-08-01 | Pyrotinib, Pertuzumab | Dr. Reddy's Laboratories, HLB Life Science, Jiangsu Hengrui Pharmaceuticals | Breast Cancer | Phase 3 | NCT04973319 |
| 2027-08-01 | Adebrelimab | Jiangsu Hengrui Pharmaceuticals | Small Cell Lung Cancer | Phase 3 | NCT05496166 |
| 2027-08-01 | Cadonilimab | Akeso | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 3 | NCT05587374 |
| 2027-08-01 | BFB759 | Bluefin Biomedicine | Hidradenitis Suppurativa | Phase 2/3 | NCT07287644 |
| 2027-08-01 | Roflumilast (Daliresp) | AstraZeneca | NAFLD (Nonalcoholic Fatty Liver Disease) | Phase 2/3 | NCT07900087 |
| 2027-08-02 | Osimertinib | AstraZeneca | Non-Small Cell Lung Cancer | Phase 3 | NCT05120349 |
| 2027-08-04 | Elranatamab | Pfizer | Multiple Myeloma | Phase 3 | NCT05317416 |
| 2027-08-07 | Tofersen | Biogen, Ionis Pharmaceuticals | Amyotrophic Lateral Sclerosis | Phase 3 | NCT04856982 |
| 2027-08-07 | Capecitabine | Cheplapharm Arzneimittel GmbH | Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour | Phase 3 | NCT07185672 |
| 2027-08-09 | Golcadomide | Bristol-Myers Squibb | Large B-Cell Lymphoma | Phase 3 | NCT06356129 |
| 2027-08-10 | Zigakibart | Novartis | Chronic Kidney Disease, IgA Nephropathy | Phase 3 | NCT05852938 |
| 2027-08-17 | Nivolumab, Atigotatug | Bristol-Myers Squibb, Ono Pharmaceutical | Small Cell Lung Cancer | Phase 3 | NCT06646276 |
| 2027-08-17 | baricitinib | Eli Lilly, Incyte | Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, Baricitinib | Phase 2/3 | NCT07449910 |
| 2027-08-20 | Zodasiran | Arrowhead Pharmaceuticals | Homozygous Familial Hypercholesterolemia | Phase 3 | NCT07037771 |
| 2027-08-20 | maridebart cafraglutide | Amgen | Obesity | Phase 3 | NCT07225686 |
| 2027-08-24 | Ravulizumab | AstraZeneca | Myasthenia Gravis, Generalized Myasthenia Gravis | Phase 3 | NCT07596784 |
| 2027-08-25 | Apatinib | Advenchen Laboratories, Elevar Therapeutics, Inc., HLB Life Science | Gastric Cancer, Surgery | Phase 3 | NCT07314203 |
| 2027-08-27 | Etavopivat | Novo Nordisk | Sickle Cell Disease | Phase 3 | NCT06612268 |
| 2027-08-27 | BLU-5937 | GlaxoSmithKline | Refractory Chronic Cough | Phase 3 | NCT07650084 |
| 2027-08-28 | HDM1005 | Hangzhou Zhongmei Huadong Pharmaceutical | Type 2 Diabetes | Phase 3 | NCT07394114 |
| 2027-08-30 | Methotrexate | Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity | Phase 3 | NCT04483466 | |
| 2027-08-30 | VC005 | Hangzhou Zhongmei Huadong Pharmaceutical, Jiangsu Vcare Pharmatech | Atopic Dermatitis | Phase 3 | NCT06723080 |
| 2027-08-30 | Venetoclax, Azacitidine | AbbVie, Roche, Bristol-Myers Squibb | Acute Myeloid Leukemia | Phase 3 | NCT07132684 |
| 2027-08-30 | VC005 | Hangzhou Zhongmei Huadong Pharmaceutical, Jiangsu Vcare Pharmatech | Active Ankylosing Spondylitis | Phase 3 | NCT07172360 |
| 2027-08-30 | maridebart cafraglutide | Amgen | Obstructive Sleep Apnea | Phase 3 | NCT07226765 |
| 2027-08-30 | HDM1005 | Hangzhou Zhongmei Huadong Pharmaceutical | Type 2 Diabetes | Phase 3 | NCT07417306 |
| 2027-08-31 | Durvalumab | AstraZeneca | Non-Small Cell Lung Cancer | Phase 3 | NCT04465968 |
| 2027-08-31 | Atezolizumab, Bevacizumab | Chugai Pharma, Roche | Venous Thrombosis | Phase 3 | NCT04649489 |
| 2027-08-31 | onabotulinumtoxinA | AbbVie | Transfer Dysphagia, Oropharyngeal Dysphagia, Cricopharyngeus Muscle Dysfunction | Phase 2/3 | NCT04695600 |
| 2027-08-31 | Iparomlimab and tuvonralimab | Qilu Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT05487391 |
| 2027-08-31 | tovecimig | Compass Therapeutics | Biliary Tract Cancer | Phase 2/3 | NCT05506943 |
| 2027-08-31 | Gotistobart | OncoC4, Inc. | Non-Small Cell Lung Cancer | Phase 3 | NCT05671510 |
| 2027-08-31 | Obinutuzumab, tocilizumab | Roche, Chugai Pharma | Lymphoma | Phase 3 | NCT06084936 |
| 2027-08-31 | Cannabidiol (Epidiolex) | GW Pharmaceuticals, Jazz Pharmaceuticals | Generalized Anxiety Disorder (GAD), Anxiety Disorders | Phase 3 | NCT07123467 |
| 2027-08-31 | Inebilizumab | Amgen, Hansoh Pharmaceutical Group, Tanabe Pharma Corporation | Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | NCT07132398 |
| 2027-08-31 | Ferric carboxymaltose | Daiichi Sankyo, Vifor Pharma | Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular | Phase 2/3 | NCT07217873 |
September 2027
October 2027
November 2027
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2027-11 (month only) | Carfilzomib, Lenalidomide, Dexamethasone | Amgen, Ono Pharmaceutical, Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT02659293 |
| 2027-11 (month only) | Pirtobrutinib | Eli Lilly | Mantle Cell Lymphoma | Phase 3 | NCT04662255 |
| 2027-11 (month only) | Donanemab | Eli Lilly | Alzheimer's Disease | Phase 3 | NCT05026866 |
| 2027-11 (month only) | Treprostinil (Tyvaso) | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | NCT05943535 |
| 2027-11 (month only) | Finerenone | Bayer | Heart Failure | Phase 3 | NCT06008197 |
| 2027-11 (month only) | Empagliflozin, Finerenone | Boehringer Ingelheim, Eli Lilly, Bayer | Heart Failure | Phase 3 | NCT06024746 |
| 2027-11 (month only) | Olomorasib | Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT06119581 |
| 2027-11 (month only) | Ubrogepant (Ubrelvy) | AbbVie | Migraine | Phase 3 | NCT06417775 |
| 2027-11 (month only) | soquelitinib | Angel Pharmaceuticals, Corvus Pharmaceuticals | Peripheral T-Cell Lymphoma | Phase 3 | NCT06561048 |
| 2027-11 (month only) | tasimelteon | Vanda Pharmaceuticals | Insomnia Disorder | Phase 3 | NCT06953869 |
| 2027-11 (month only) | Iloperidone (Fanapt) | Vanda Pharmaceuticals | Schizophrenia | Phase 3 | NCT06961968 |
| 2027-11 (month only) | Direclidine | Neurocrine Biosciences, Nxera Pharma | Schizophrenia | Phase 3 | NCT07105098 |
| 2027-11 (month only) | SHR-1819 | Jiangsu Hengrui Pharmaceuticals | Atopic Dermatitis | Phase 3 | NCT07309055 |
| 2027-11 (month only) | efpeglenatide | Hanmi Pharmaceutical, Laboratorios Sanfer | Type 2 Diabetes | Phase 3 | NCT07379333 |
| 2027-11 (month only) | Enavogliflozin | Arcera Life Sciences, Daewoong Pharmaceutical | Type 2 Diabetes | Phase 3 | NCT07619833 |
| 2027-11 (month only) | CM512 | Belenos Biosciences, Keymed Biosciences | Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) | Phase 3 | NCT07807826 |
| 2027-11-01 | Methotrexate, Rituximab, Dexamethasone | Biogen, Chugai Pharma, Roche | Acute Lymphoblastic Leukemia | Phase 3 | NCT03150693 |
| 2027-11-01 | Venetoclax, Azacitidine | AbbVie, Roche, Bristol-Myers Squibb | Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2/3 | NCT04256317 |
| 2027-11-01 | Abemaciclib, Ribociclib, Capivasertib, Palbociclib | Eli Lilly, Novartis, Astex Pharmaceuticals, Inc. | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT04862663 |
| 2027-11-01 | Durvalumab, Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | Non-Small Cell Lung Cancer | Phase 3 | NCT05687266 |
| 2027-11-01 | Olanzapine (Zyprexa) | Cheplapharm Arzneimittel GmbH, Eli Lilly | Misuse, Opioid | Phase 3 | NCT06200181 |
| 2027-11-01 | Azacitidine, Ivosidenib | Bristol-Myers Squibb, Servier | Myelodysplastic Syndromes | Phase 3 | NCT06465953 |
| 2027-11-01 | Tislelizumab | BeOne Medicines | Colorectal Cancer, Microsatellite Instability High | Phase 3 | NCT06520683 |
| 2027-11-01 | Suzetrigine | Vertex Pharmaceuticals | Total Hip Arthroplasty (THA), Total Hip Arthroplasty \(THA\), Total Hip Replacement, Total Hip Replacement Surgery, Total Hip Replacements, Total Hip Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials | Phase 3 | NCT07226700 |
| 2027-11-04 | tozorakimab | AstraZeneca | Viral Lung Infection and Acute Respiratory Failure | Phase 3 | NCT05624450 |
| 2027-11-05 | rilzabrutinib | Sanofi | Immune Thrombocytopenia | Phase 3 | NCT07007962 |
| 2027-11-05 | Risvutatug rezetecan | GlaxoSmithKline, Hansoh Pharmaceutical Group | Small Cell Lung Cancer | Phase 3 | NCT07099898 |
| 2027-11-07 | Semaglutide (Ozempic) | Novo Nordisk | Type 2 Diabetes | Phase 3 | NCT03811561 |
| 2027-11-08 | Fenfluramine | Nippon Shinyaku, UCB | Epilepsy | Phase 3 | NCT05064878 |
| 2027-11-11 | Bexicaserin | H. Lundbeck | Epilepsy | Phase 3 | NCT06908226 |
| 2027-11-12 | spesolimab | Boehringer Ingelheim, LEO Pharma | Pyoderma Gangrenosum | Phase 3 | NCT06624670 |
| 2027-11-14 | Exagamglogene autotemcel (Casgevy) | CRISPR Therapeutics, Vertex Pharmaceuticals | Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies | Phase 3 | NCT05356195 |
| 2027-11-14 | Bofanglutide | A. Menarini, Gan & Lee Pharmaceuticals, JW Pharmaceutical | Obesity | Phase 3 | NCT07493057 |
| 2027-11-15 | Ixoberogene soroparvovec | Eli Lilly | Wet Age-Related Macular Degeneration | Phase 3 | NCT07482176 |
| 2027-11-16 | Daratumumab, Iberdomide, Dexamethasone | Johnson & Johnson, Bristol-Myers Squibb | Multiple Myeloma | Phase 3 | NCT04975997 |
| 2027-11-17 | Cadonilimab, Capecitabine | Akeso, Cheplapharm Arzneimittel GmbH | Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | NCT07449780 |
| 2027-11-18 | Ropeginterferon alfa-2b (Besremi) | AOP Orphan Pharmaceuticals GmbH, PharmaEssentia Corporation | Myelofibrosis | Phase 3 | NCT06468033 |
| 2027-11-19 | Docetaxel, Pasritamig | Sanofi, Johnson & Johnson | Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer | Phase 3 | NCT07225946 |
| 2027-11-20 | Camrelizumab | Elevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals | Nasopharyngeal Carcinoma | Phase 3 | NCT06669611 |
| 2027-11-26 | Volrustomig | AstraZeneca | Cervical Cancer | Phase 3 | NCT06079671 |
| 2027-11-26 | Enlicitide | Merck & Co. | Atherosclerotic Cardiovascular Disease, Hypercholesterolemia | Phase 3 | NCT07821944 |
| 2027-11-30 | metformin | Medulloblastoma, Childhood, Cognitive Impairment | Phase 3 | NCT05230758 | |
| 2027-11-30 | ExoFlo | Direct Biologics | Acute Respiratory Distress Syndrome, ARDS | Phase 3 | NCT05354141 |
| 2027-11-30 | Clifutinib Besylate | Shenyang Sunshine Pharmaceutical, Sunshine Lake Pharma | Acute Myeloid Leukemia | Phase 3 | NCT05586074 |
| 2027-11-30 | Risvutatug rezetecan | GlaxoSmithKline, Hansoh Pharmaceutical Group | Small Cell Lung Cancer | Phase 3 | NCT06526624 |
| 2027-11-30 | Capivasertib, Fulvestrant | Astex Pharmaceuticals, Inc., AstraZeneca | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT06764186 |
| 2027-11-30 | Ravulizumab | AstraZeneca | Delayed Graft Function, DGF, Kidney Transplant | Phase 3 | NCT06830798 |
| 2027-11-30 | Regorafenib, Fruquintinib, Anbenitamab repodatecan | Bayer, HUTCHMED, Takeda Pharmaceutical Company | Colorectal Cancer | Phase 3 | NCT07384377 |
December 2027
Source: ClinicalTrials.gov, each study's record, checked daily. Studies that are terminated, withdrawn or completed are left out, as are programmes their developer has stopped. A month-only date is shown as given.